Clinical Trials Logo

Obesity clinical trials

View clinical trials related to Obesity.

Filter by:

NCT ID: NCT00231621 Terminated - Obesity Clinical Trials

A Study on Efficacy and Safety of Topiramate in Treatment of Obese Subjects With Dyslipidemia

Start date: May 2001
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the efficacy and safety of daily topiramate versus placebo for the treatment of obese subjects with dyslipidemia.

NCT ID: NCT00229229 Terminated - Obesity Clinical Trials

Comparison of 4 Diets in the Management of Overweight Patients With Vascular Disease

Start date: September 2004
Phase: Phase 4
Study type: Interventional

Type 2 diabetes can be prevented by lifestyle changes in high-risk subjects. However, controversies exist on nutritional management of diabetes. Recent data suggests that glucose and insulin responses are affected by not only the quality, but the quantity of carbohydrate consumed. This is referred to as glycemic load. To date, there have not been any prospective randomized studies which examine the utility of a low glycemic load diet. The purpose of the proposed study is to compare the effectiveness of a Canada Food Guide Diet with a low glycemic load diet on blood sugar control in overweight type 2 diabetics.

NCT ID: NCT00228176 Terminated - Obesity Clinical Trials

Atherosclerosis Underlying Development Assessed by Intima-Media Thickness in Patients on Rimonabant (Auditor)

Start date: August 2005
Phase: Phase 3
Study type: Interventional

Objectives: - Primary: To evaluate the effect of rimonabant 20-mg once daily in comparison with placebo, on the quantitative progression of atherosclerosis as assessed by carotid artery intima-media thickness (CIMT) - Secondary: To evaluate the safety and tolerability of the above rimonabant regimen in the study population of atherosclerosis patients.

NCT ID: NCT00207389 Terminated - Obesity Clinical Trials

A Study to Examine Changes in GIP Plasma Levels Following Gastric Bypass Surgery in Obese Patients

Start date: March 2004
Phase: N/A
Study type: Observational

Obesity is a multinational epidemic. There is evidence that despite educational measures and increased public awareness, the number of obese individuals continues to increase. Of the numerous obesity-related comorbidities, type 2 diabetes remains one of the most significant in terms of mortality and health care costs. Gastric Bypass Surgery (GBS) not only offers an effective form of therapy for morbid obesity, but also amelioration of type 2 diabetes mellitus. The normalization of glucose levels in GBS patients occurs within days after surgery and has been shown in surgical literature to be independent of the weight loss after surgery. The proximal gut, the site of release of certain incretins, may play a role in glucose homeostasis in obese individuals with type 2 diabetes mellitus. One such incretin is GIP, which when released into the circulation during the immediate postprandial period, accentuates the insulin response to a glucose meal. It is hypothesized that overactivity of this enteroinsular axis in obese individuals produces cell resistance to insulin and subsequent type 2 diabetes mellitus. A previous study reported elevated fasting GIP levels, as well as an exaggerated GIP response to a glucose meal, in obese subjects, which was significantly reduced months after GBS following weight loss. This pilot study of obese patients scheduled for GBS will compare the serum levels of certain peptides, including GIP, following a glucose meal before and after GBS, before weight loss has occured. In order to reproduce the preoperative state, and therefore to demonstrate the physiologic change, a small group of subjects who undergo open surgery will undergo the same measurements after surgery, but using a model in which the meal traverses the stomach, duodenum and jejunum with the aid of a gastrostomy tube.

NCT ID: NCT00198809 Terminated - Obesity Clinical Trials

Use of Herbal Supplements in Weight Loss and Weight Maintenance

Start date: November 2002
Phase: N/A
Study type: Interventional

Effects of herbal products on weight loss, weight maintenance and metabolic rate. - The objective of this study is to evaluate the efficacy of two herbal weight loss products, BioLean and BioLean Free compared to each other and a matching placebo, in effects on appetite suppression, changes in metabolism, weight loss, and safety in overweight men and women over a 12 month active weight loss and weight maintenance program. - This is a randomized double-blind study. The planned sample size is 180 healthy, overweight (BMI 27-40) males and females aged 18-60.

NCT ID: NCT00143078 Terminated - Obesity Clinical Trials

Obesity and Weight Loss on Reproductive Function

Start date: June 2005
Phase: Phase 2
Study type: Observational

The purpose of this study is to examine how obesity and weight loss following bariatric surgery affect reproductive function. The study is particularly interested in how changes in hormones (those produced in the stomach and fat tissue) following weight loss affect reproductive function. Specifically, we, the researchers at Penn State University, propose to characterize reproductive abnormalities in morbidly obese men and women. We hypothesize that morbid obesity leads to reproductive abnormalities in men and women. We plan to examine the short-term effects of alteration in GI hormones after bariatric surgery on reproductive function. We hypothesize that bariatric surgery radically alters GI hormone expression, resulting in immediate changes to the hypothalamic-pituitary-gonadal axis in men and women. Lastly, we, the researchers, plan to examine the long-term effects of weight loss and changes in adipokines on reproductive function. We hypothesize that the changes in adipokine levels resulting from fat mass reduction lead to substantial long-term improvements in reproductive function and fertility. We also hypothesize that there are sexual dimorphisms in adipokine levels following weight loss, with women experiencing larger changes than men.

NCT ID: NCT00131404 Terminated - Obesity Clinical Trials

A Two Year Safety and Efficacy Study in Obese Patients (0364-015)(TERMINATED)

Start date: September 2005
Phase: Phase 3
Study type: Interventional

A study to determine the safety and efficacy of an investigational drug in patients with obesity plus extension.

NCT ID: NCT00131391 Terminated - Obesity Clinical Trials

A Study of MK0364 in Obese Patients (0364-014)

Start date: July 2005
Phase: Phase 3
Study type: Interventional

A worldwide study in obese patients to assess the efficacy, safety, and tolerability of an investigational drug.

NCT ID: NCT00120562 Terminated - Obesity Clinical Trials

Studies of Biological Changes Related to Weight Loss After Gastric Bypass Surgery

Start date: July 2007
Phase: Phase 2
Study type: Observational

Weight loss achieved by dieting induces multiple changes. These changes include a decrease in metabolic rate (the rate in which the body burns its calories), an increase in appetite and other physiological and hormonal changes that may be the cause of failure in dieting. Many of these parameters that have never been evaluated when weight is lost after gastric bypass surgery will be tested in this study.

NCT ID: NCT00115063 Terminated - Obesity Clinical Trials

LOSS- Louisiana Obese Subjects Study

LOSS
Start date: July 2005
Phase: Phase 4
Study type: Interventional

LOSS is a pragmatic clinical evaluation of intensive medical approaches to weight loss for individuals with extreme obesity (body mass index [BMI] 40-60 kg/m2). The intensive medical treatment is designed to produce 25% weight loss from baseline and to maintain at least 20% weight loss from baseline. The intensive medical treatment is compared to a usual care treatment model where individuals utilize self directed approaches to weight loss. The active treatment period is three years, followed by two years of observation.